HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Trazodone in the treatment of panic disorder and agoraphobia with panic attacks.

Abstract
Eleven patients with panic disorder or agoraphobia with panic attacks completed an 8-week single-blind trial of trazodone (300 mg/day) without concurrent behavioral instructions. The measures of change included ratings of generalized and panic anxiety, phobias, and depression and a behavioral avoidance test, which were administered during a baseline period of placebo administration and at 4 and 8 weeks of the trial. There was significant improvement on all symptom dimensions, which suggests that trazodone may have specific antipanic and antiphobic actions and underscores the importance of serotonergic mechanisms in these anxiety disorders.
AuthorsM Mavissakalian, J Perel, K Bowler, R Dealy
JournalThe American journal of psychiatry (Am J Psychiatry) Vol. 144 Issue 6 Pg. 785-7 (Jun 1987) ISSN: 0002-953X [Print] United States
PMID3296792 (Publication Type: Clinical Trial, Journal Article, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Trazodone
Topics
  • Adult
  • Agoraphobia (drug therapy, psychology)
  • Ambulatory Care
  • Anxiety Disorders (drug therapy, psychology)
  • Clinical Trials as Topic
  • Fear
  • Female
  • Humans
  • Male
  • Outcome and Process Assessment, Health Care
  • Panic
  • Personality Inventory
  • Phobic Disorders (drug therapy)
  • Psychiatric Status Rating Scales
  • Trazodone (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: